Supira Medical, a Campbell, Calif.-based developer of a percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures, raised $15.5M in funding.
The round was led by The Capital Partnership (TCP) with participation from Cormorant Asset Management and Shifamed Angels.
Led by Jean Orth, CEO, Supira Medical is focused on the development of a percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures.
Supira is the newest portfolio company of Shifamed, which, since 2009, has incubated and sold three portfolio companies with an additional three companies funded and in development. Shifamed’s legacy portfolio companies include Maya Medical (acquired by Covidien), Kalila Medical (acquired by Abbott/Terumo), and most recently Apama Medical (acquired by Boston Scientific). The current portfolio consists of Atia Vision developing a next generation of accommodating intraocular lens, NuVera Medical developing a novel imaging platform for use during complex cardiovascular interventions, and its most recent addition Supira Medical.